Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Marta Torres-Ferrús"'
Autor:
Robert Belvís, Pablo Irimia, Patricia Pozo-Rosich, Carmen González-Oria, Antonio Cano, Javier Viguera, Belén Sánchez, Francisco Molina, Isabel Beltrán, Agustín Oterino, Elisa Cuadrado, Angel Gómez-Camello, Miguel Alberte-Woodward, Carmen Jurado, Teresa Oms, David Ezpeleta, Javier Díaz de Terán, Noemí Morollón, Germán Latorre, Marta Torres-Ferrús, Alicia Alpuente, Raquel Lamas, Carlos Toledano, Rogelio Leira, Sonia Santos, Margarita Sánchez del Río
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract Background Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official r
Externí odkaz:
https://doaj.org/article/fcecd02650084384bd50ba7605c09f88
Autor:
Alicia Alpuente, Victor J. Gallardo, Laila Asskour, Edoardo Caronna, Marta Torres-Ferrus, Patricia Pozo-Rosich
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Migraine is a complex neurological disorder with significant heterogeneity in its clinical presentation and molecular mechanisms. Calcitonin gene-related peptide (CGRP) has emerged as a key player in migraine pathophysiology, but
Externí odkaz:
https://doaj.org/article/b9c8613f71db4ae7bd153bd7c9d4fcf7
Autor:
Carlos Lazaro-Hernandez, Edoardo Caronna, Joana Rosell-Mirmi, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Migraine is one of the main causes of disability worldwide. Anti-CGRP monoclonal antibodies (MAbs) have proven to be safe and efficacious as preventive migraine treatments. However, their use is restricted in many countries due to
Externí odkaz:
https://doaj.org/article/002b1a3b20cf45ffa8bdf62cd3d41a3c
Autor:
Angela Marti-Marca, Adrià Vilà-Balló, Xim Cerda-Company, Nara Ikumi, Marta Torres-Ferrus, Edoardo Caronna, Victor J. Gallardo, Alicia Alpuente, Mireia Torralba Cuello, Salvador Soto-Faraco, Patricia Pozo-Rosich
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-31 (2023)
Abstract Background Migraine is a cyclic, neurosensory disorder characterized by recurrent headaches and altered sensory processing. The latter is manifested in hypersensitivity to visual stimuli, measured with questionnaires and sensory thresholds,
Externí odkaz:
https://doaj.org/article/b5d6a9d4296542c797e8aa565c33c466
Autor:
Laura Gómez-Dabó, Edoardo Caronna, Rut Mas-de-les-Valls, Víctor J. Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Publikováno v:
Toxins, Vol 16, Iss 5, p 221 (2024)
Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature on BTX-A use in the pediatric po
Externí odkaz:
https://doaj.org/article/5f5583c8e5fd489798253db754fa17ce
Autor:
Albert Muñoz-Vendrell, Sergio Campoy, Edoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, Candela Nieves Castellanos, Marina Olivier, Jaume Campdelacreu, Joan Prat, Javier Camiña Muñiz, Francisco José Molina Martínez, Ane Mínguez-Olaondo, Marta Ruibal Salgado, Sonia Santos Lasaosa, María Pilar Navarro Pérez, Noemí Morollón, Alba López Bravo, Luis Miguel Cano Sánchez, Sonia María García-Sánchez, Jésica García-Ull, Laura Rubio-Flores, Alicia Gonzalez-Martinez, Sonia Quintas, Ana Echavarría Íñiguez, Sendoa Gil Luque, María Victoria Castro-Sánchez, Vanesa Adell Ortega, Jessica García Alhama, Nuria Berrocal-Izquierdo, Robert Belvís, Samuel Díaz-Insa, Patricia Pozo-Rosich, Mariano Huerta-Villanueva
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-9 (2023)
Abstract Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-wo
Externí odkaz:
https://doaj.org/article/22bda9ea46154712b0bfdabad461f143
Autor:
Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, Marta Torres-Ferrus, Patricia Pozo-Rosich
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Patient-Reported Outcomes (PROs) have been developed to numerically quantify disability, impact and quality of life. They have been widely used in migraine clinical trials. However, we still do not know which PRO more accurately r
Externí odkaz:
https://doaj.org/article/d0e2bb029c04427b8f5770e5c05b4b98
Autor:
Edoardo Caronna, Victor José Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-7 (2021)
Abstract Background In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their effectiveness in a real-life clinical cohort. Methods This is a
Externí odkaz:
https://doaj.org/article/271116c36a2b4edfa440fc159127d7ab
Autor:
Marta Torres-Ferrus, Deborah Pareto, Victor J Gallardo, Gemma Cuberas-Borrós, Alicia Alpuente, Edoardo Caronna, Adrià Vila-Balló, Carles Lorenzo-Bosquet, Joan Castell-Conesa, Alex Rovira, Patricia Pozo-Rosich
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-11 (2021)
Abstract Background To describe interictal brain structural and metabolic differences between patients with episodic migraine (EM), chronic migraine (CM) and healthy controls (HC). Methods This is an exploratory study including right-handed age-match
Externí odkaz:
https://doaj.org/article/aa7f0df0ff1843b29c866f6381ad2fd5
Autor:
Marta, Torres-Ferrús, Manuel, Toledo, Montserrat, González-Cuevas, Laia, Seró-Ballesteros, Esteban, Santamarina, Miquel, Raspall-Chaure, María, Sueiras-Gil, Roser, Cambrodí-Masip, Silvana, Sarria, José, Álvarez-Sabín, Javier, Salas-Puig
Publikováno v:
Revista de neurologia. 57(7)
The aetiology of epilepsy is an important decisive factor in its treatment and prognosis. Diagnostic and therapeutic advances suggest that the causal distribution, treatment and prognosis of the population with epilepsy may have undergone some modifi